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Background: Bone graft substitutes are widely used for reconstruction of posttraumatic bone defects. However,
their clinical significance in comparison to autologous bone grafting, the gold-standard in reconstruction of larger
bone defects, still remains under debate. This prospective, randomized, controlled clinical study investigates the
differences in pain, quality of life, and cost of care in the treatment of tibia plateau fractures-associated bone defects
using either autologous bone grafting or bioresorbable hydroxyapatite/calcium sulphate cement (CERAMENT™|
BONE VOID FILLER (CBVF)).
Methods/Design: CERTiFy (CERament™ Treatment of Fracture defects) is a prospective, multicenter, controlled,
randomized trial. We plan to enroll 136 patients with fresh traumatic depression fractures of the proximal tibia
(types AO 41-B2 and AO 41-B3) in 13 participating centers in Germany. Patients will be randomized to receive either
autologous iliac crest bone graft or CBVF after reduction and osteosynthesis of the fracture to reconstruct the
subchondral bone defect and prevent the subsidence of the articular surface. The primary outcome is the SF-12
Physical Component Summary at week 26. The co-primary endpoint is the pain level 26 weeks after surgery
measured by a visual analog scale. The SF-12 Mental Component Summary after 26 weeks and costs of care will
serve as key secondary endpoints. The study is designed to show non-inferiority of the CBVF treatment to the
autologous iliac crest bone graft with respect to the physical component of quality of life. The pain level at 26 weeks
after surgery is expected to be lower in the CERAMENT bone void filler treatment group.
Discussion: CERTiFy is the first randomized multicenter clinical trial designed to compare quality of life, pain, and
cost of care in the use of the CBVF and the autologous iliac crest bone graft in the treatment of tibia plateau
fractures. The results are expected to influence future treatment recommendations.
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Background and rationale
Tibial plateau fractures (TPF) are caused by both low-
energy or high-energy excessive varus or valgus forces
combined with axial stress on the knee [1]. High-energy
fractures are commonly the result of traffic accidents,
falls, or sports-related injuries. Low-energy fractures are
mainly seen in older individuals due to reduced bone
mineral density and are typically associated with a de-
pression of the articular surface. In all cases, depressed
articular components require meticulous anatomical reduc-
tion and stable osteosynthesis to allow early rehabilitation.
The depression of the articular surface may be associated
with a metaphyseal defect, which often requires additional
reconstruction procedures with autologous bone grafts or
bone graft substitutes to improve healing and prevent sub-
sidence of the articular surface [2]. Due to its favorable bio-
logical and biomechanical features [3-5], autologous iliac
bone grafting (AIBG) has been considered a gold standard
especially to reconstruct bone voids of large sizes and frac-
ture non-unions even in metaphyseal and diaphyseal areas.
However, some well-recognized complications associated
with graft harvesting including pain at the donor site, nerve
injury, hematoma, infection and pelvic fracture at the donor
site [6-8] may significantly influence the quality of life
(QoL) of those patients [9]. In addition, both prolonged op-
eration time and hospital stay after bone graft harvesting
may unnecessarily complicate the surgical treatment [9,10].
To address such shortcomings and to develop a non-
invasive alternative to AIBG, the quality of synthetic
bone graft substitutes has been increasingly improved in
the last two decades [11]. In a non-controlled cohort study
with a mean follow-up of 22.2 months bone union was
achieved in all patients and remodeling of the bone substi-
tute in 89% in depressed tibia plateau fractures [12]. In a
prospective, randomized study on 119 patients with tibia
plateau fractures treated with a bioresorbable calcium
phosphate cement or autologous iliac bone graft the au-
thors showed comparable union rates and times to union
in the two groups. Interestingly, a significantly higher rate
of articular subsidence was observed in the bone graft
group [13].
Other studies on this topic focused on clinical and
functional outcomes [14]. Bioactive glass has been com-
pared to autologous bone in a randomized clinical study
for the treatment of tibia plateau fractures. This study
with 25 patients found the same clinical outcome in the
two groups [15]. Clinical and functional outcome param-
eters have been investigated to compare autologous bone
grafts and bone graft substitutes in several studies. How-
ever, the endpoints used in these studies were strongly
related to the quality of the surgery rather than to the
quality of the bone graft material itself. None of the pub-
lished studies investigated parameters such as pain, qualityof life or cost of care, which may really reflect the conse-
quences of the bone harvesting. On the other hand these
parameters are also suitable to assess the effects of the
bone substitute material quality, which is critical for the
defect healing and prevention of the secondary subsidence
of the joint surface. Therefore, investigation of these out-
come parameters in a sufficiently powered, prospective,
randomized, controlled clinical trial is highly necessary.
CERAMENT™ BONE VOID FILLER (CBVF) is one of
the widely used bone substitute materials, which was re-
ported to promote cancellous bone healing and reprodu-
cible remodeling in bone defects [16]. It consists of 60%
calcium sulfate (CS) and 40% hydroxyapatite (HA) and
has been previously investigated in an open wedge ra-
dius osteotomy study showing convincing results. The
aim of this study is to compare the impact of CBVF and
autologous bone graft on QoL, pain, and costs of care in
a standardized tibial plateau fracture (AO-Types 41-B2
and AO 41-B3 (Figure 1)) that are associated with a sig-
nificant bone defect.
Primary hypothesis
We assume that six months after surgical treatment no
relevant mean differences will be present for the SF-12-
PCS (Short Form 12 Physical Component Summary
Score) and that pain level (determined by Visual Analog
Score, VAS) will be lower in patients treated with CBVF
compared to autologous cancellous bone grafts in tibia
plateau fractures types AO 41-B2 and AO 41-B3.
Methods/Design
The CERTiFy (CERament treatment of Tibial Fracture
defects) trial is a prospective, open-label, multicenter,
controlled, randomized clinical trial. The study will com-
prise 136 patients with acute traumatic depression fractures
of the proximal tibia (limited to AO type 41-B2 & B3) from
13 different trauma centers in Germany. Patients are ran-
domized to receive either an autologous cancellous bone
graft taken from the iliac crest or CBVF.
Eligibility criteria
Patients between the age of 18 and 65 years with a solitary,
acute, traumatic, closed depression fracture of the prox-
imal tibia (limited to AO types 41 B2 & B3, Schatzker
types II and III) (Figures 2, 3, and 4) requiring reconstruc-
tion of the subchondral bone void are enrolled into the
trial. The ability to understand the procedure of participat-
ing in the study and to comply with the follow-up pro-
gram is a prerequisite. Only patients with a maximum
interval of one week between injury and intervention will
be included.
Patients will be excluded from the study if the respon-
sible surgeons request treatment in which the principle
of therapeutic uncertainty is violated. Clinical exclusion
Figure 1 AO classification of tibia plateau fractures (B2 and B3). (‘Copyright by AO Foundation, Davos, Switzerland - Müller AO Classification
of Fractures’).
Figure 2 Anteroposterior (a-p) X-ray of the knee showing an
AO 41 B3.1 fracture type.
Figure 3 Lateral X-ray of the knee showing an AO 41 B3.1
fracture type.
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Figure 4 Coronal reconstructions of a computed tomography
(CT) scan of the knee showing an AO 41 B3.1 fracture type.
Nusselt et al. Trials 2014, 15:75 Page 4 of 11
http://www.trialsjournal.com/content/15/1/75criteria involve patients with more than one injury, poly-
trauma patients, compartment syndrome, previous iliac
crest bone graft harvesting, local infection at the site of
implantation, chronic pain disease, malignancy, rheuma-
toid arthritis, chronic cortisone therapy, unavailable X-ray
diagnostics, doubtful fracture classification, and clinically
significant unstable medical or surgical conditions that
may preclude safe and complete study participation.
Device-related exclusion factors are pre-existing calcium
metabolism disorders (for example, hypercalcemia), hyper-
thyroidism, or autonomous thyroid adenoma, a history of
serious reaction to iodine-based radio contrast agents,
pregnancy or breastfeeding (a pregnancy test will be per-
formed at screening visit), irreversible coagulopathy or
bleeding disorders, history of physical or psychological
condition that contraindicates the use of an investigational
device or render the patient at high risk from treatment
complications, as well as history of hypersensitivity to the
device or any of its ingredients. Participation in other clin-
ical trials during the present clinical trial or within the last
month will be also considered an exclusion criterion.
Randomization
After giving consent to participate in the study, patients
will be randomized by a web-based randomization toolprovided by IZKS Mainz allowing investigators to ran-
domize patients via a secure web interface. Randomization
will be stratified by age group (18 to 39 years; 40 to 65 years)
and gender. Block randomization with variable block sizes
will be applied.
Interventions
All fractures will be immobilized with a plaster cast until
surgical treatment. Centers may follow their preferred
standard operating procedures and locally established
protocols for pain management. These modalities will be
precisely documented.
Operative treatment
After randomization, all patients will be operated as soon
as possible, depending on local soft tissue conditions,
hematoma, and swelling. Open reduction and internal fix-
ation will be performed via an anterolateral approach
using screws and buttress plate for stabilization after re-
duction of the depressed articular surface according to the
AO principles of fracture care. The protocol does not spe-
cify the use of specific hardware. The bone defect, which
is created after reduction of the depressed articular frag-
ments, will be reconstructed either with an autologous
cancellous bone graft from the iliac crest or with the
CBVF (Figures 5 and 6). All surgeons performing the op-
eration have proven expertise with the procedure and are
familiar with the implants and devices used in this study.
Outcome measures
Primary outcome
The primary endpoint in this study is the SF-12 v2 Physical
Component Summary (PCS) score (4 week standard recall
version) at week 26 after the intervention. The co-primary
endpoint is pain VAS measurement at week 26 after the
intervention. The SF-12 is a subset from items of the
SF-36, which is the most widely used generic health
assessment questionnaire worldwide.
Secondary outcomes
The SF-12v2 Mental Component Summary (MCS) at week
26 and costs of care related resources will be evaluated as
key secondary endpoints.
Services relevant to cost of care will be estimated from
the type of insurance (private or compulsory), days spent
in the hospital as the result of the trauma, total costs of
care for the hospital stay in Euro, DRG (diagnosis-related
group) code and the number of lump compensations for
ambulant treatment. In addition, the patient will be asked
to document the costs of care for services related to
trauma and applied outside the trial center (for example,
physiotherapy, medical aids) beginning with the day of
discharge from the trial center. The assessment of costs
Figure 6 Postoperative lateral X-ray of the knee showing the
reconstruction result.
Figure 5 Postoperative anteroposterior (a-p) X-ray of the knee
showing the result of reconstruction. The subchondral bone
defect was filled with CBVF.
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will be performed in German centers only.Other endpoints
SF-12v2 PCS and SF-12v2 MCS will be assessed as add-
itional endpoints at visits 4 to 6, the pain measured by
VAS (visits 3 to 6) as well as the intake of pain medica-
tion at visits 3 to 7. Fracture healing and integrity of the
articular surface will be assessed using standard anteropos-
terior and lateral views of plain radiographs. The radio-
graphs will be reviewed by the panel of two experienced
orthopedic trauma surgeons and one consultant who will
be blinded as to the kind of material used. The panel will
independently review all radiographs in chronological order.
The loss of reduction and subsidence of the articular sur-
face will be recorded and analyzed using the Rasmussen
score [17], in which articular subsidence, condylar widen-
ing, and varus or valgus deviation will be quantitatively
assessed over a period of 26 weeks. In addition, the panelwill evaluate fracture union, bone defect remodeling as well
as loss or premature resorption of the graft using the fol-
lowing point score:
1. Osteolysis, premature resorption of the graft
2. Unchanged size of the void, no resorption of the
bone graft
3. Beginning marginal bone defect remodeling
4. Bone defect remodeling with undirected formation
of trabecula
5. Bone defect remodeling with directed formation of
trabecula
Complications (for example, hardware failure and dis-
placement, wound healing problems, infections, revisions,
neurologic impairment, pressure ulcers and others) as well
as all adverse events (AE) will be recorded and regularly
evaluated throughout the study.
Evaluation and follow-up
Clinical evaluation and trial documentation consist of
seven visits: screening (V1), intervention (V2) and five
postoperative follow-up examinations ending with V7
after 26 weeks (Table 1).
Table 1 Visit schedule
Visit no 1 2 3 4 5 6 7§
Day −7 – 0 Day 0 Day 1 Day 7 Week 6 Week 12 Week 26




Patient employment status X
Medical history X
Weight and Height X
Physical examination X
Vital signs (pulse, blood pressure) X
Pregnancy test (women of childbearing potential) X
Concomitant medication/therapy X X X X X X X
Evaluation of CT scan* X
Evaluation of X-ray findings* X X X X X X
Randomization X
Surgery** (autologous bone graft or treatment
with CBVF***)
X
Procedure information (type and amount of bone graft,
hardware used, etc. - time of surgery)
X
Adverse events X X X X X X X
Device complaints X X X X X X
Clinical examination (pain, tenderness,
warmth and swelling)
X X X X
Documentation of treatments performed outside
the trial center****
Pain medication X X X X X X X
SF-12v2TM X X X X X
Pain (VAS) X X X X X X
End of the trial X
*Computed tomography (CT) and X-ray assessments are performed as a clinical routine according to the standards of care. They will be not performed for the
purposes of the study. **Surgical procedures are performed according to the standard of care. No surgical interventions will be performed for the purposes of the
study. ***CBVF, CERAMENT™|BONE VOID FILLER. ****Continuous documentation by patient, when applicable. §These examinations should also be performed at
the trial end visit in case the patient prematurely drops out of the trial.
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The trial aims and procedures will be explained to the
patient by responsible local investigators using a study
information booklet. After informed consent is given,
the screening visit (V1) will be performed within 7 days
prior to day of surgery (day 0). After radiological assess-
ment of the fracture type, baseline demographics, co-
morbidity, medication, and pregnancy test (if applicable)
will be evaluated and verification of inclusion and exclu-
sion criteria performed. The trial participant will be elec-
tronically randomized to one of the two treatment arms
using a web-based tool. All data will be documented
using an electronic case report form (eCRF). Assessment
of the VAS and SF-12v2 scores will be performed at the
end of the V1.V2 - intervention
This visit is intended to document the surgical procedures
and procedure-related complications. In both treatment
arms the responsible surgeon performs the intervention.
The test device is administered according to the in-
struction for use (IFU) for CBVF. Fracture surgery and,
if applicable, harvesting of autologous bone graft will
be performed according to the well-established stan-
dards of care.
After the surgery, information on the type of surgery,
osteosynthesis material, volume of CBVF or autologous
cancellous bone graft are documented in the eCRF. Fur-
thermore, adverse events including the device complaints
will be documented as well. Postoperative care is performed
according to the local SOPs.
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Radiographs are taken between day 1 to day 3 to evaluate
the quality of reduction of the articular surface as well as
the appropriate positioning of the hardware and the device.
Furthermore, adverse events including device complaints,
the VAS score, and concomitant medication including pain
medication will be documented in the eCRF.V4 - day 7 post intervention
The following procedures will be performed: evaluations
of the X-rays, monitoring of adverse events including de-
vice complaints, the SF-12v2 score, VAS, concomitant
medication including pain medication, and clinical healing
evaluation (pain, tenderness, warmth, and swelling).V5 - 6 weeks post intervention and V6 - 12 weeks post
intervention
Patients will be evaluated in an outpatient clinic by the
responsible surgeon. Results of the radiological assess-
ment which is required according to the standard of care
will be documented in the eCRF. Possible local complica-
tions such as pain, tenderness, warmth, and swelling will
be assessed. The number of physiotherapy courses and the
need for other therapeutic interventions will be docu-
mented in the patient’s diary. Adverse events including de-
vice complaint monitoring, the SF-12v2 score, VAS, and
concomitant medication including pain medication will be
recorded.V7 - 26 weeks post intervention, final visit
The final visit will be performed six months after the
intervention. The results of the clinical and radiological
evaluation as well as the adverse events and device com-
plaints will be documented in the eCRF. The SF-12v2
score, the VAS score and medication will be assessed and
recorded. Computed tomography scans (CTs) and x-rays
will be sent anonymously to coordinating investigator for
central blinded evaluation.Statistics
Pre-specification
Details of the statistical analysis of the data collected in
this trial will be documented in a Statistical Analysis Plan
(SAP) that will be generated by IZKS Mainz and finalized
before closing the database. The SAP is based on the
protocol including all amendments. The document may
modify the plans outlined in this protocol; however any
major modifications of the primary endpoint definition
and/or its analysis will also be reflected in a protocol
amendment. Any deviation from the original SAP must be
described and justified in the final report. The statistical
analysis will be conducted by means of SAS™.Sample size and power calculation
Sample size was calculated for the primary endpoint
(SF-12v2 PCS week 26). Additional power calculations
were performed for the co-primary endpoint (VAS pain
score week 26). Within the German norm population,
mean SF-12v2 PCS is 50 and the standard deviation is
10 [18]. The study population is expected to come very
close to this German norm population. Based on the in-
clusion criteria (age between 18 and 65) and demo-
graphic data of the proximal tibia fractures treated at the
trial site in Mainz between 2009 and 2011, it seems jus-
tified to expect the SF-12v2 PCS results 26 weeks after
surgery to be 50 ± 10 (mean ± standard deviation) in both
treatment groups. The non-inferiority margin was defined
as 5 points on the SF-12v2 PCS scale (range: 0–100). This
value is half of the expected standard deviation in the refer-
ence population. Since changing one of the SF-12v2 items
affecting SF-12v2 PCS by one category causes SF-12v2
PCS to change by at least 3 points, the non-inferiority
margin corresponds to less than two items changed by
one response category. Under these assumptions, a shifted
two-sample t-test with a one-sided significance level of
2.5% and a power of 80% requires 128 patients to show
that mean SF-12v2 PCS 26 weeks after surgery in patients
treated with CBVF is not more than 5 points lower com-
pared to the control group. Since 5% of randomized pa-
tients are expected to be ineligible for the primary Per
Protocol Analysis, 136 patients will be randomized. Pain
assessed by VAS after 26 weeks is expected to be 2 (80%)
or 1 (20%) in the control group and 2 (10%), 1 (20%) or 0
(70%) in the CBVF treatment group. Based on these as-
sumptions, the probability that pain assessed on a VAS
comparing one randomly selected patient in each group
is higher in the patient treated with CBVF is 14%. A
Wilcoxon-Mann–Whitney-Test comprising 128 patients
will have a power of >99% to show at a two-sided sig-
nificance level of 5% that the above specified probability
is <50%.
Analysis populations
The intention to treat (ITT) population comprises all
randomized patients, even if the planned surgery/surger-
ies did not take place. The modified intention to treat
(mITT) population includes all randomized patients for
which the primary endpoint could be assessed (that is,
SF-12 PCS assessment is available both preoperatively
and 26 weeks after surgery). Patients are eligible for the
per protocol (PP) population, if they fulfill the following
criteria: eligible for the mITT population, no violation of
inclusion criteria, not meeting any exclusion criteria, trial
treatment as randomized, time interval between Visit 2
(day 0, surgery) and Visit 7 (week 26): 22 to 30 weeks, ab-
sence of events with a strong effect on quality of life but
definitely unrelated to the randomized study treatment
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follow-up, or accident).
The safety population comprises all randomized subjects
who received trial treatment (autologous bone graft or
Treatment with CBVF). In analyses of the safety popula-
tion, subjects will be assigned to the treatment they actu-
ally received.
Efficacy analysis
Within the primary analysis of this study, SF12v2 summary
scores are not normalized to the reference population.
Nevertheless, normalized z and t scores of SF12v2 sum-
mary scores will be calculated in explorative analyses. SF-
12v2 standard 4-weeks recall version will be used within
this study. The confirmatory efficacy analysis is planned
using a hierarchical testing procedure. In the first step, dif-
ferences between SF-12v2 PCS are tested by an analysis of
covariance (ANCOVA) with SF-12v2 PCS at week 26 as
the dependent variable and SF-12v2 PCS at screening, age
group (18–39; 40–65), gender, and treatment as covariates.
If the covariate-adjusted two-sided 95% confidence interval
of the treatment effect within this model (difference of
SF-12v2 PCS, experimental treatment group - control
group) is located completely above the non-inferiority
margin of −5, non-inferiority of CBVF with respect to
Physical Component of Quality of Life 26 weeks after
surgery will be claimed. The primary endpoint will be
primarily analyzed in the PP population. Only if non-
inferiority can be claimed in the first step, pain as the
co-primary endpoint may be tested in a confirmatory
way. Differences between pain assessed by VAS 26 weeks
after surgery will be tested by a Wilcoxon-Mann–Whitney-
U-Test at a two-sided significance level of 5%. Analysis will
be done primarily for the mITT population. Within this
hierarchical testing procedure, a global significance level of
5% is ensured. The power was not adjusted since the local
power of the second test (pain assessment) is sufficiently
large (>99%). In order to check robustness of confirmatory
results, supportive analyses of both (co-)primary endpoints
will be performed in the mITT, PP and ITT populations.
Models with a modified set of covariates (for example, trial
site and surgical technique) will also be calculated as sup-
portive analyses. Analyses in the ITT population will re-
quire imputing missing data. Multiple imputation methods
are planned within this context. Further details will be
specified in the Statistical Analysis Plan. All secondary
endpoints will be analyzed using appropriate methods de-
pending on the scale of the respective parameter. Analyses
of secondary endpoints will be interpreted exploratively.
Safety analysis
All summaries and listings of safety data will be performed
for the safety population. Frequencies of subjects experien-
cing at least one adverse event (AE) will be displayed bybody system and preferred term according to MedDRA
terminology. Detailed information collected for each AE
will include: a description of the event, duration, whether
the AE was serious, intensity, relationship to trial treat-
ment, action taken, and clinical outcome. Summary tables
will present the number of subjects observed with AEs and
corresponding percentages. Additional subcategories will
be based on event intensity and relationship to trial treat-
ment. Analysis of device (CBVF)/graft (autologous bone)
complaints will be analogously as far as possible.
Withdrawal criteria
Patients can withdraw their consent without giving rea-
sons for withdrawal at any time point of the study. The
withdrawal will not have any negative consequences for
the participant. The participation in this study may be
discontinued:
1. upon the request of the sponsor for safety reasons
2. upon the request of a regulatory agency
3. if serious adverse events related to the therapy
occurred
4. in case of non-compliance of participant
5. if participation in the trial would be of potential
hazard to study participant´s health
6. if study participant will need a treatment which is
specified in the protocol as exclusion criterium
7. if study participant becomes pregnant
Participants withdrawn from the study will not be re-
placed regardless of the reason for withdrawal. The in-
vestigator decides about the withdrawal of study until
resolve of symptoms, but no longer than 6 months after
the subject’s withdrawal from the trial.
Assessments of safety
All adverse events (AE) and serious adverse events (SAE),
including device-related events will be assessed und docu-
mented. Some AE may lead to secondary surgical inter-
ventions. According to the Good Clinical Practice (GCP)
guidelines, secondary surgical interventions will be catego-
rized as follows:
1. A revision is a procedure that adjusts or in any way
modifies or removes part of the original implant
configuration, with or without replacement of
component. A revision may also include adjusting
the position of the original configuration.
2. A removal is a procedure where the entire original
system configuration is removed with or without
replacement.
3. A reoperation is any surgical procedure at the
involved site that does not remove, modify or add
any components to the system.
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additional instrumentation not under study in the
protocol is implanted (for example, supplemental
placement of a rod/screw system or a plate/screw
system).
5. All these secondary surgical interventions will be
considered serious adverse events.
According to the Food and Drug Administration (FDA)
definition, a device complaint is any written, electronic or
oral communication that alleges deficiencies related to the
identity, quality, durability, reliability, safety effectiveness,
or performance of a device. All kinds of AEs (whether ser-
ious or non-serious) reported by the subject or detected
by the investigator will be documented in the eCRF and in
the patient´s medical records.
Trial documentation and data collection
A detailed methodology for the data management in this
trial will be documented in a data management plan
(DMP) that will be dated and maintained by IZKS Mainz.
The data acquisition will be performed using a web-based
electronic case report form (eCRF). The investigator will
enter the data via remote data entry (RDE) directly into the
trial database, developed and maintained by IZKS Mainz.
The system will be secured to prevent unauthorized access
to the data or the system. The system provides the option
of making exact data copies in legible paper form for re-
view and audits. The investigator or a designated sub-
investigator, following review of the data in the eCRF, will
confirm the validity of each subject’s data by electronic sig-
nature or by signing a paper printout of all trial´s data.
Checks for plausibility, consistency, and completeness of
the data will be performed during and after data entry.
After completion of data entry and if no further correc-
tions are to be made in the database, the access rights will
be taken away and the database will be declared closed and
used for statistical analysis. All data management activities
will be done according to the current standard operating
procedures (SOPs) of IZKS Mainz. The names of the study
participants and all other confidential information will be
handled according to the medical professional secrecy and
the regulations of the German Federal Data Protection
Act. None of the patient-related information will become
available to any person who is not directly involved in the
medical treatment. During the clinical trial, subjects will be
identified solely by means of an individual identification
code. All trial results stored on a computer will be handled
in accordance with the local data protection law in strictest
confidence. For protection of these data, organizational
procedures are implemented to prevent distribution of
data to unauthorized persons. The appropriate regula-
tions of data legislation will be fulfilled in its entirety.
The subject will declare in the written consent to releasethe investigator from the medical professional secrecy
to allow identification of subject’s name and/or inspec-
tion of original data for monitoring purposes by author-
ities and authorized persons.
Source of bias
To reduce ascertainment bias, QOL and pain assessments
will be performed by independent surgeons who will not
be directly involved in the operative treatment of the pa-
tients. Furthermore, the assessments will be performed by
persons with broad experience in treating trauma patients
to determine whether or not events impacting QOL are
really related to the treatment. The assessors will docu-
ment all relevant events potentially impacting QOL and
pain in the trial report. However, a consequent blinding of
the assessors will not be feasible, since an additional wound
will be obvious in all patients of the autologous bone graft
group. Therefore, the method of assessment may be associ-
ated with an ascertainment bias, which cannot be avoided
completely by the study design.
Ethical issues
The procedures set out in the trial protocol, pertaining to
the conduct, evaluation, and documentation of this trial,
are designed to ensure that all persons involved in the trial
abide by Good Clinical Practice [19] and the ethical princi-
ples described in the Declaration of Helsinki [20]. The trial
is carried out in compliance with local legal and regulatory
requirements. Prior to enrollment of the first subject, all
ethical and legal requirements will be met by inclusive un-
reserved approval by institutional review boards. The final
study protocol and the final version of the written in-
formed consent form were already approved by the ethics
committee of the University of Mainz, which is responsible
for the site of the principal investigator. Medical experts
have performed the critical assessments of risks and bene-
fits in advance. Each site’s principal investigator ensures
that all persons assisting with the trial are adequately in-
formed about the protocol, the trial treatments, and their
trial related duties and functions. Before being enrolled
into the clinical trial, each subject must consent to par-
ticipate after nature, scope, and possible consequences
of the clinical trial have been explained to him or her in
an understandable oral and written form. The subject
must give consent in writing or orally in presence of an
independent witness before randomization. Results of
study will be published according to the most recent
version of the Consolidated Standards of Reporting Trials
statement [21].
Discussion
Autogenous cancellous bone from the iliac crest is the
most frequently used site for bone-graft harvest and re-
mains to be the 'gold standard’ in reconstruction of bone
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http://www.trialsjournal.com/content/15/1/75defects and fracture non-unions in both metaphyseal
and diaphyseal areas. The co-morbidities related to har-
vesting of autologous bone grafts are well documented
[4,22-26]. Bone substitutes are used to avoid donor site
problems associated with the harvest of the iliac crest
bone graft. The clinical and functional outcome when
comparing the use of autologous bone graft with the use
of a bone graft substitute has been investigated in several
studies [8,13,22,27]. However, the endpoints of those studies
were mostly related to the ‘quality’ of the surgery per-
formed. Good clinical outcome is directly related to the
quality of the anatomical reduction of tibial plateau frac-
tures [13,28]. Tibia plateau fractures have a high incidence
of reduction loss when fixed without augmentation of the
depressed articular fragments [4,29]. Actually, there are no
studies that compare pain, QoL, and costs of care, which
are all relevant endpoints related to the bone graft used.
This necessitates the investigation of these outcomes in a
sufficiently powered, prospective, randomized, controlled
clinical trial. Current evidence, specifically reliable informa-
tion from RCTs, is insufficient to counsel patients and their
relatives with regard to the most convenient, efficient, and
safe method to avoid prolonged pain and to restore a high
level of quality of life and activity. As far as we know, the
CERTiFy trial is the first randomized multicenter RCT that
aims at generating conclusive evidence on the most appro-




AE: adverse event; AIBG: autologous iliac bone graft; ANCOVA: analysis of
covariance; AO: Arbeitsgemeinschaft Osteosynthese; CBVF: CERAMENT bone
void filler; CE: Communautés Européennes; CERTiFy: CERAMENT treatment of
fracture defects; CPC: calcium phosphate cements; CRF: case report form;
CS: calcium sulfate; CT: computed tomography; DMP: data management
plan; DRG: diagnosis related group; eCRF: electronic case report form;
FDA: Food and Drug Administration; GCP: good clinical practice;
HA: hydroxyl apatite; IFU: instruction for use; ITT: intention to treat;
IZKS: Interdisziplinäres Zentrum für Klinische Studien Mainz; MCS: Mental
Component Score; mITT: modified intention to treat; ORIF: open reduction
and internal fixation; PCS: Physical Component Summary; PP: per protocol;
Qol: quality of life; RCT: randomized controlled trial; RDE: remote data entry;
SAE: serious adverse event; SAP: statistical analysis plan; SAS: statistical
analysis system; SF-12v2: Short Form 12 Version 2; SF-12v2-PCS: Short Form
12 Version - physical component score; SF12v2-MCS: Short Form 12 Version
2 - mental component score; SF-36: Short Form 36 score; SOP: standard
operating procedure; VAS: Visual Analog Scale.
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